KRTCAP2

Across TCGA pan-cancer cohorts, KRTCAP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRTCAP2 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher KRTCAP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTCAP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where KRTCAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.235	0.688	.004	23	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.335	.024	10	view →
PDAC	DFS	Tertile	IV	0.199	0.934	.024	9	view →
UCEC	DFS	Quartile	III,IV	0.232	1.000	.038	4	view →
LSCC	DFS	Median	II,III,IV	0.278	0.915	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KRTCAP2–CCRCC (DFS)

Open the CCRCC breakdown →